Annual Oncology Symposium:

Controversies in Hematologic Malignancies

Friday, May 20, 2016
Glaser Auditorium
Swedish First Hill
747 Broadway
Seattle, Washington
Needs Statement

Research shows that thousands of patients with hematologic malignancies are not receiving a diagnosis of their condition until it is too late in the disease process to provide treatment that may increase their chance of survival. This is the result of a lack of awareness of the symptoms of hematologic malignancies by both health professionals and the public. Approximately 54,270 new cases of leukemia are diagnosed each year that will result in an estimated 24,450 deaths. In addition, over 80,000 new cases of lymphoma are expected to be diagnosed annually, resulting in an estimated 20,840 deaths. While death rates have been declining slowly in these and other hematologic malignancies, advancing treatment options, targeted therapy and genetic profiling could further improve survival rates. As there are no means of prevention or early screening for most blood cancers, primary care providers and hematologic oncology providers alike must be on the lookout for symptoms and have knowledge of the newest treatment options and protocols. This will enable these health care professionals to select the most appropriate tests and treatment options for their individual patients and provide them with the best chances of survival.

Course Description

Utilizing didactic lectures, case presentations and multidisciplinary discussion panels on controversial hematology oncology topics, this symposium will review the tools and techniques health care professionals can, and should, utilize to diagnose and treat hematologic malignancies (leukemia, lymphoma and myeloma). Nationally-recognized, expert faculty will also cover unique treatment considerations for different age groups and address the overall needs of the whole patient and their families to ultimately improve patient care and survivorship.

Intended Audience

This conference is intended for all health-care professionals involved in the care of oncology patients in the Northwest, including physicians, physician assistants, advanced practice nurses, nurses, pharmacists, allied health professionals, residents/fellows and researchers. It is especially relevant for the following specialties: hematology oncology, medical oncology, radiation oncology, surgery, pathology, primary care, family medicine, internal medicine, research, genetic counseling, palliative care, social work and naturopathy.

Course Objectives

At the conclusion of this symposium, the participant will provide better patient care through an increased ability to:

- Identify the new drugs and approaches for treating leukemia patients in 2016, determine the risk associated with these new therapies and utilize newly available drugs.
- Use molecular monitoring to follow patients with leukemia, select frontline and salvage therapy and review when to consider a trial of treatment-free remission.
- Determine the risk and benefits between standard Acute Myeloid Leukemia (AML) induction therapies and those directed to Myelodysplastic Syndromes (MDS), assess the outcome of patients treated in each manner and determine the appropriate role of transplantation.
- Define patient populations appropriate for aggressive therapy for leukemia, assess parameters for making the decisions for aggressive therapy, identify the adverse events associated with each approach and determine how these factors affect outcomes in older patients.
- Diagnose Chronic Lymphocytic Leukemia (CLL), recognize the biologic prognostic factors and compare and contrast the traditional treatment of CLL and promising new treatment options.
- Define aggressive double hit and other more aggressive features of Diffuse Large B-Cell Lymphoma (DLBCL) and select the unique treatment for each of these entities.
- Assess the new era of immunotherapies, review checkpoint inhibitors and adoptive immunotherapies and recognize how immunotherapies should be used in lymphoma therapy.
- Define the new novel therapies utilized in T-cell Non-Hodgkin Lymphoma (NHL) therapy and the risks and benefits of each approach, identify the appropriate patients for transplantation and assess the most consistent transplant approach to improve outcomes.
- Describe the incorporation of new, novel therapies into therapy in both the frontline and relapsed settings for patients with lymphoma and review how to approach these patients once they have failed a standard approach to treatment for NHL.
- Recognize and assess the high-risk features of myeloma and the tests needed to select the appropriate treatments for patients with high-risk myeloma in 2016.
- Master the criteria for what constitutes high-risk disease, apply the new myeloma staging system that incorporates features of high-risk disease and recognize the effectiveness of novel agents in reducing the impact of high-risk features.
- Determine the role of stem cell transplantation for myeloma in 2016 and the risks and benefits of each approach, recognize when to refer a patient for stem cell transplant and manage the care of the patient effectively after the transplant.
- Discuss special considerations and evidence-based recommendations for diagnosing and treating elderly myeloma patients versus other age groups.
- List the unique medical and psychosocial challenges faced by Adolescent and Young Adult (AYA) cancer patients, describe how selection of treatment protocol and location of care can affect outcome in AYAs with cancer and recognize the key goals and components of a comprehensive AYA cancer program.
- Recognize patients appropriate for Hospice Referral, review the Medicare Hospice Benefit and recognize Hospice and Palliative Medicine as a continuum of care.
- Review palliative care recommendations for hematologic malignancies with expert faculty and discuss current controversies in palliative care.
7:20 a.m.  Registration and Continental Breakfast
7:50 a.m.  Welcome and Introductions
John M. Pagel, M.D., Ph.D.

Section 1:  Leukemia
Moderator: Raya Mawad, M.D.

8:00 a.m.  Acute Leukemia: New Drugs and Regimens in 2016
Charles A. Schiffer, M.D.

8:30 a.m.  Optimizing Chronic Myelogenous Leukemia (CML) Therapy – A 2016 Perspective
Michael Deininger, M.D., Ph.D.

9:00 a.m.  Should Myelodysplastic Syndromes (MDS) Be Treated like Acute Myeloid Leukemia (AML)?
Bart Scott, M.D.

9:30 a.m.  Panel Discussion: Chemotherapy in the Elderly – How Old is Too Old?
Moderator: Raya Mawad, M.D.
Panel: Michael Deininger, M.D., Ph.D.; Charles A. Schiffer, M.D.; Bart Scott, M.D.

9:50 a.m.  Break

Section 2:  NHL/CLL
Moderator: John M. Pagel, M.D., Ph.D.

10:05 a.m.  New Treatment of Chronic Lymphocytic Leukemia (CLL)
John C. Byrd, M.D.

10:35 a.m.  How to Treat Diffuse Large B-Cell Lymphoma (DLBCL) Subtypes Including Double Hit in 2016
Keron Dunleavy, M.D.

11:05 a.m.  Immunotherapy Approaches for Lymphoma
John Kuruvilla, M.D.

11:35 a.m.  Controversies and Approaches to T-Cell Lymphoma Therapy in 2016
Steven Horwitz, M.D.

11:55 a.m.  Panel Discussion: How to Sequence Treatments for Indolent Lymphomas
Moderator: John M. Pagel, M.D., Ph.D.
Panel: John C. Byrd, M.D.; Keron Dunleavy, M.D.; Steven Horwitz, M.D.; John Kuruvilla, M.D.

12:15 p.m.  Lunch

Section 3:  Myeloma
Moderator: Michael S. Milder, M.D., FACP

1:00 p.m.  How Should We Sequence New Treatment Options Based on Molecular Abnormalities for Myeloma in 2016?
Thomas Martin, M.D.

1:30 p.m.  How I Treat High-Risk Myeloma
Morie Gertz, M.D., MACP

2:00 p.m.  Role of Transplantation for Myeloma in 2016
William Bensinger, M.D.

2:30 p.m.  Panel Discussion: Age-Specific Considerations: Understanding the Elderly Myeloma Patient
Moderator: Michael S. Milder, M.D., FACP
Panel: William Bensinger, M.D.; Morie Gertz, M.D., MACP; Thomas Martin, M.D.

3:00 p.m.  Break

Section 4:  Care of Young and Older patients: Specialized Approaches, Palliative Care, and Survivorship
Moderator: Jon Younger, M.D.

3:05 p.m.  Adolescent and Young Adult (AYA) Care in 2016 – Why Does It Matter?
Rebecca Johnson, M.D.

3:35 p.m.  Hospice – Palliative Care in the Last Six Months of Life
Gregg VandeKieft, M.D. and Marian McNamara, M.D.

4:05 p.m.  Panel Discussion: Controversies in Palliative Care
Moderator: Jon Younger, M.D.
Panel: Ellyn M. Lee, M.D., FACP; Marian McNamara, M.D.; Gregg VandeKieft, M.D.

4:25 p.m.  Adjourn
William Bensinger, M.D.
Hematologist/Oncologist
Center for Blood Disorders and Stem Cell Transplantation
Swedish Cancer Institute

John C. Byrd, M.D.
Professor, Director, Division of Hematology
The Ohio State University

Michael Deininger, M.D., Ph.D.
Chief, Division of Hematology and Hematologic Malignancies
M.M. Wintrobe Professor of Medicine
University of Utah
Senior Director of Transdisciplinary Research Huntsman Cancer Institute

Kieron Dunleavy, M.D.
Clinical Director
Lymphoid Malignancies Branch
Staff Clinician
Center for Cancer Research
National Cancer Institute

Morie Gertz, M.D., MACP
Chair, Department of Medicine
Mayo Clinic Minnesota

Steven Horwitz, M.D.
Associate Attending
Memorial Sloan Kettering Cancer Center

Rebecca Johnson, M.D.
Medical Director
Adolescent and Young Adult Cancer Program
Mary Bridge Hospital / MultiCare Health System

John Kuruvilla, M.D.
Hematologist
Princess Margaret Cancer Centre
Associate Professor of Medicine
University of Toronto

Ellyn M. Lee, M.D., FACP
Medical Director, Palliative Care
Swedish Cancer Institute

Thomas Martin, M.D.
Professor of Clinical Medicine
Associate Director Grand MMTI
University of California, San Francisco

Raya Mawad, M.D.
Hematologist/Oncologist
Center for Blood Disorders and Stem Cell Transplantation
Swedish Cancer Institute

Marian McNamara, M.D.
Chief Medical Director
Providence Hospice

Michael S. Milder, MD, FACP
Hematologist/Oncologist
Center for Blood Disorders and Stem Cell Transplantation
Swedish Cancer Institute

Charles A. Schiffer, M.D.
Professor of Medicine and Oncology
Joseph Dresner Chair for Hematologic Malignancies
Chief, Multidisciplinary Leukemia/Lymphoma Group
Wayne State University School of Medicine Karmanos Cancer Institute

Bart Scott, M.D.
Associate Member
Fred Hutchinson Cancer Research Center
Associate Professor
University of Washington Medical Center

Gregg VandeKieft, M.D.
Medical Director, Palliative Care
Providence Olympia, Washington

Jon Younger, M.D.
Chief Medical Officer
Swedish Medical Group

Planning Committee
John M. Pagel, M.D., Ph.D., Course Co-chair
Kirsten Alcorn, M.D.
Ami L. Batchelder, PA-C
William Bensinger, M.D., Course Co-chair
George Birchfield, M.D.
Caye Boosalis, MEd, CME Manager
David Dong, M.D., Ph.D.
Eileen Galvin, RN
Erin Kieper
Ellyn M. Lee, M.D., Ph.D.
Kristin Mantei, M.D.
Raya Mawad, M.D.
Michael S. Milder, MD, FACP
Elizabeth M. Ranker, PA-C
Jon Younger, M.D.
Danielle Westley, CME Specialist
Accreditation with Commendation
Swedish Medical Center is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

AMA PRA Category 1 Credits™
Swedish Medical Center designates this live activity for a maximum of 7.25 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

AAFP Prescribed Credits
Application for CME credit has been filed with the American Academy of Family Physicians. Determination of credit is pending.

Nursing CE Contact Hours
Swedish Medical Center Clinical Education and Practice is an approved provider of continuing nursing education by the Washington State Nurses Association Continuing Education Approval & Recognition Program (CEARP), an accredited approver by the American Nurses Credentialing Center’s Commission on Accreditation.

Acknowledgments
This symposium is financially supported in part by educational grants in accordance with ACCME’s Standards for Commercial Support. At the time of this printing, a complete listing of commercial supporters was not available. Appropriate acknowledgment will be given to all supporters at the time of the symposium.

Registration Information:
Pre-registration is required as space is limited. Participants who register by the “Advance Registration” deadline will receive a confirmation postcard after Monday, May 9, 2016. Registrations will only be processed when accompanied by full payment.

If using the registration form, please mail or fax it to:
Continuing Medical Education
Swedish Medical Center
747 Broadway
Seattle, WA 98122
Fax: 206-320-7462

Cancellation: To receive a refund, notice of cancellation must be received no later than Friday, May 13, 2016.

Please note: No registrations are accepted by phone or e-mail.

If you have special needs, please contact the CME office at 206-386-2755.

Registration Fees: The fee for this course includes catering, all instruction and hands-on materials, online syllabus access and a certificate of AMA PRA Category 1 Credits™.

For Further Information:
Phone: 206-386-2755
Fax: 206-320-7462
E-mail: CME@swedish.org
Web: swedish.org/CME

Location
Swedish Medical Center First Hill is located at 747 Broadway in Seattle, Washington. The conference will be held in the Glaser Auditorium on the first floor of the medical center. Parking is available in the Broadway Garage at 747 Broadway at a maximum fee of $12. From I-5 (northbound and southbound), take the James Street exit. Travel east on James Street. Turn left (north) onto Broadway. Turn left into the main hospital entrance and follow the signs to the Broadway underground parking garage.

Annual Oncology Symposium: Controversies in Hematologic Malignancies
Friday, May 20, 2016

Please print or type information

NAME

TITLE/CREDS

ADDRESS

CITY/STATE/ZIP

PHONE

FAX

E-MAIL

EMERGENCY CONTACT NAME & PHONE NUMBER (OPTIONAL)

SPECIALTY

Registration Fees

<table>
<thead>
<tr>
<th>Advance Registration</th>
<th>After May 9</th>
</tr>
</thead>
<tbody>
<tr>
<td>M.D. or D.O.</td>
<td>$250</td>
</tr>
<tr>
<td>Allied Health Professional</td>
<td>$125</td>
</tr>
<tr>
<td>Medical Student</td>
<td>$25</td>
</tr>
<tr>
<td>Resident/Fellow</td>
<td>$25</td>
</tr>
</tbody>
</table>

☐ Check enclosed, payable to Swedish CME
☐ Credit Card #
☐ Visa ☐ MasterCard ☐ Discover ☐ AMEX

Signature __________________________ Expiration Date _______
Annual Oncology Symposium:
Controversies in Hematologic Malignancies

Friday, May 20, 2016
Glaser Auditorium
Swedish First Hill
747 Broadway
Seattle, Washington